104 related articles for article (PubMed ID: 19689339)
1. Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy.
Tur MK; Neef I; Jäger G; Teubner A; Stöcker M; Melmer G; Barth S
Curr Pharm Des; 2009; 15(23):2693-9. PubMed ID: 19689339
[TBL] [Abstract][Full Text] [Related]
2. Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells.
Tur MK; Neef I; Jost E; Galm O; Jäger G; Stöcker M; Ribbert M; Osieka R; Klinge U; Barth S
J Immunother; 2009 Jun; 32(5):431-41. PubMed ID: 19609235
[TBL] [Abstract][Full Text] [Related]
3. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
[TBL] [Abstract][Full Text] [Related]
4. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
6. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
7. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
8. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
9. Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins.
Tur MK; Daramola AK; Gattenlöhner S; Herling M; Chetty S; Barth S
Biomedicines; 2017 Oct; 5(4):. PubMed ID: 28976934
[TBL] [Abstract][Full Text] [Related]
10. CD30 as a therapeutic target for lymphoma.
Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo.
Hirsch B; Brauer J; Fischdick M; Loddenkemper C; Bulfone-Paus S; Stein H; Dürkop H
Curr Drug Targets; 2009 Feb; 10(2):110-7. PubMed ID: 19199906
[TBL] [Abstract][Full Text] [Related]
12. Death-associated protein kinase 2 is a new calcium/calmodulin-dependent protein kinase that signals apoptosis through its catalytic activity.
Kawai T; Nomura F; Hoshino K; Copeland NG; Gilbert DJ; Jenkins NA; Akira S
Oncogene; 1999 Jun; 18(23):3471-80. PubMed ID: 10376525
[TBL] [Abstract][Full Text] [Related]
13. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
14. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.
Bhatt G; Maddocks K; Christian B
Curr Hematol Malig Rep; 2016 Dec; 11(6):480-491. PubMed ID: 27613003
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxins in targeted cancer cell therapy.
Reiter Y
Adv Cancer Res; 2001; 81():93-124. PubMed ID: 11430597
[TBL] [Abstract][Full Text] [Related]
16. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
Wendtner CM; Schmitt B; Gruss HJ; Druker BJ; Emmerich B; Goodwin RG; Hallek M
Cancer Res; 1995 Sep; 55(18):4157-61. PubMed ID: 7545087
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapeutic RNases (ImmunoRNases).
Schirrmann T; Krauss J; Arndt MA; Rybak SM; Dübel S
Expert Opin Biol Ther; 2009 Jan; 9(1):79-95. PubMed ID: 19063695
[TBL] [Abstract][Full Text] [Related]
18. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
[TBL] [Abstract][Full Text] [Related]
19. New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo.
Braschoss S; Hirsch B; Dübel S; Stein H; Dürkop H
Leuk Lymphoma; 2007 Jun; 48(6):1179-86. PubMed ID: 17577782
[TBL] [Abstract][Full Text] [Related]
20. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
